Clinical trials: HIV Reservoir
Human Immunodeficiency Virus (HIV)
The Effect of Ixazomib on the Latent HIV Reservoir
The primary purpose of the trial is to determine the safety and tolerability of ixazomib in HIV infected patients on antiretroviral therapy.
- Trial name
- NCT02946047
- Testing
- Ixazomib 1 MG, Ixazomib 2 MG, Ixazomib 3 MG
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Mayo Clinic
HIV, Human Immunodeficiency Virus
Short-term Disulfiram Administration to Reverse Latent HIV Infection: a Dose Escalation Study
The purpose of this study is to determine the safety, pharmacology and bioactivity of disulfiram in antiretroviral treated HIV-infected adults.
- Trial name
- NCT01944371
- Testing
- Disulfiram
- Where
- 2 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- University of California, San Francisco
HIV Infection
Modulating the Impact of Critical Events in Early HIV Infection: Effect of ART Initiation and Alcohol Use
The overall objective is to determine the influence of timing of ART initiation and alcohol consumption on HIV disease course. ART initiation immediately after HIV infection largely results in smaller HIV reservoir and lower…
- Trial name
- MERLIN (NCT02744040)
- Testing
- ART initiation at time of HIV diagnosis, ART at 24 weeks
- Where
- Peru
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Fred Hutchinson Cancer Center
HIV-1 Infection
Pilot Peg-Interferon-a2b in Decreasing Viral DNA in HIV
We propose to test our primary hypothesis that treatment with Peg-IFN-α-2b will result in a decrease in integrated HIV DNA in peripheral blood and tissue in chronically HIV-infected immune-reconstituted individuals (see section…
- Trial name
- NCT01935089
- Testing
- Pegylated Interferon alpha 2b
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- The Wistar Institute
HIV-1 Infection
Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy (ART)
The purpose of this study was to find out about the safety of sirolimus in individuals with HIV infection who were also being treated with ART.
- Trial name
- NCT02440789
- Testing
- Sirolimus
- Where
- 10 sites in United States
- Volunteers
- 32 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections